NVP-BSK805 (Synonyms: BSK 805;BSK-805;BSK805;NVP-BSK 805) |
Catalog No.GC13229 |
A potent, selective JAK2 inhibitor
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1092499-93-8
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Kinase experiment [1]: | |
Enzymatic Assays |
The human JAK2 kinase domain (amino acids 840 ~ 1132) was contained in plasmid construct pAcG2TtevJAK2. The plasmid constructs for JAK3 (813 ~ 1124), TYK2 (888 ~ 1187) and JAK1 (866 ~ 1154) were designed. The generation of the recombinant baculoviruses with BD BaculoGoldTM Bright linearized DNA, plaque assay, and virus amplification from single plaques was performed according to the manual (BD Biosciences Pharmingen). Janus kinase domains were expressed in Sf9 cells in 400 mL shake flasks with 100 mL ExCell420 culture medium (JRH Biosciences Ltd) with Penicillin/Streptomycin solution for 48 hrs at 27°C. Suspension culture cells were infected at a density of 1 × 106 and the multiplicity of infection (MOI) for each virus was optimized for yield of soluble protein. The kinase domain of human JAK2 and of JAK1, JAK3, and TYK2 was expressed at an MOI of 1 and 0.5, respectively. Time of expression at 27°C was 48 hrs for JAK2 and 48 hrs or 72 hrs for JAK1, JAK3, and TYK2. Forty-eight or seventy-two hrs post-infection, the cells from a 100 mL expression culture were harvested by centrifugation at 3000 × g for 5 mins and lysed with 12 mL lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 mM DTT, 1 mM sodium orthovanadate, 1 % Triton X-100, 10 % glycerol, 1 × EDTA-free complete protease inhibitor cocktail (Roche Diagnostics), and 12.5 U/mL Benzonase) for 30 mins at 4°C, followed by centrifugation at 14,000 × g for 45 mins to pellet insoluble material. For GST-tag affinity purification of kinase domain proteins, all steps were performed at 4°C. The cleared lysates were incubated with 0.2 mL of a 50 % slurry of washed Glutathione Sepharose 4B for 2 hrs at 4°C, followed by 5 washes with 1 mL of 50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % Triton X-100, 1 mM DTT, and 10 % glycerol. Bound protein was eluted in 5 aliquots each starting with a 10 mins incubation with 0.25 mL elution buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.1 % Triton X-100, 1 mM DTT, 10 % glycerol, 10 mM reduced L-glutathione). Eluates were concentrated about 5-fold with Amicon Ultra-4 spin columns. After addition of Brij35 to 0.1 % final concentration, the protein was snap frozen in small aliquots and stored at -80°C. In these conditions, kinase activities were stable for at least 6 months. The JAK kinase domain enzymes were incubated for 30 mins at room temperature in a medium containing 0.1 μM [γ33P]-ATP, 1 mM MnCl2, 5 mM MgCl2, 30 μM of synthetic peptide substrate EQEDEPEGDYFEWLE, 1 mM DTT, 1 % DMSO, 50 μg/mL BSA, 0.01 % Brij35, and 50 mM Tris-HCl pH 7.5. The ATP concentration was below the Km for all proteins. Curves were fitted by non-linear regression using the logistic equation and the global fit function of XLfit? (model 205). Expression and characterization of full-length wild type and V617F mutant JAK2 as well as kinase assay conditions had been described elsewhere. Kinase selectivity of NVP-BSK805 was assessed in an internal kinase panel: In the Caliper assays, kinase reactions were carried out with peptide substrates that migrate with different velocities in an electrical field when phosphorylated. The peptides carried a fluorescent label in order to allow the detection and quantification of the peptides in a capillary system. Peptide fluorescence intensities were quantified using the LC3000 instrument (Caliper Life Sciences, Hopkinton, MA, USA). Kinase activity was measured by quantifying the amount of ATP remaining in solution following a kinase reaction. In the LanthaScreen? TR-FRET kinase assays, terbium was used as the lanthanide chelate combined with an antibody directed against the phosphorylated substrate. |
Cell experiment [1]: | |
Cell lines |
Ba/F3 cells |
Preparation method |
Soluble in DMSO. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
Reaction Conditions |
100 nM; 72 hrs |
Applications |
NVP-BSK805 inhibited the growth of JAK2V617F cells (Ba/F3) and induced apoptosis with a GI50 at concentrations < 100 nM. |
Animal experiment [1]: | |
Animal models |
RhEpo-induced polycythemia model in female BALB/c mice |
Dosage form |
50, 75 and 100 mg/kg; p.o.; q.d. |
Applications |
At the doses of 25, 50 and 100 mg/kg, NVP-BSK805 suppressed rhEpo-induced STAT5 phosphorylation as well as rhEpo-mediated polycythemia and splenomegaly in BALB/c mice. |
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
References: [1]. Baffert F, Régnier CH, De Pover A, et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther, 2010, 9(7): 1945-1955. |
NVP-BSK805 is a potent and selective inhibitor of JAK2 with IC50 value of 0.58 nM [1].
Janus kinase 2 (JAK2) is a member of the JAK family and is a non-receptor tyrosine kinase. JAK2 regulates signal transduction in the cell nucleus via activation of signal transducers and activators of transcription proteins (STATs), which form dimers upon phosphorylation and migrate into the nucleus to regulate the activation of target genes [2].
In JAK radiometric filter binding kinase assays, NVP-BSK805 inhibited full-length JAK2 wild-type and JAK2V617F enzymes with IC50 values of 0.58 nM and 0.56 nM, respectively [1]. In CHRF-288-11, SET-2 and HEL cells which expressed JAK2, NVP-BSK805 inhibited STAT5a phosphorylation [2].
In SCID beige mice injected with JAK2V617F-dependent Ba/F3 cells, NVP-BSK805 (150 mg/kg) suppressed STAT5 phosphorylation in spleen extracts by nearly 50% relative to vehicle-treated controls at the 6- and 12-hour time. In rats injected with recombinant human erythropoietin (rhEpo), which induced transient polycythemia and splenomegaly, NVP-BSK805 suppressed rhEpo-induced STAT5 phosphorylation in spleen in a dose-dependent way [1].
References:
[1]. Baffert F, Régnier CH, De Pover A, et al. Potent and selective inhibition of polycythemia by the quinoxaline JAK2 inhibitor NVP-BSK805. Mol Cancer Ther, 2010, 9(7): 1945-1955.
[2]. Ringel F, Kaeda J, Schwarz M, et al. Effects of Jak2 type 1 inhibitors NVP-BSK805 and NVP-BVB808 on Jak2 mutation-positive and Bcr-Abl-positive cell lines. Acta Haematol, 2014, 132(1): 75-86.
Cas No. | 1092499-93-8 | SDF | |
Synonyms | BSK 805;BSK-805;BSK805;NVP-BSK 805 | ||
Chemical Name | 4-[[2,6-difluoro-4-[3-(1-piperidin-4-ylpyrazol-4-yl)quinoxalin-5-yl]phenyl]methyl]morpholine;dihydrochloride | ||
Canonical SMILES | C1CNCCC1N2C=C(C=N2)C3=NC4=C(C=CC=C4N=C3)C5=CC(=C(C(=C5)F)CN6CCOCC6)F.Cl.Cl | ||
Formula | C27H28F2N6O | M.Wt | 490.55 |
Solubility | ≥ 20.95 mg/mL in DMSO, ≥ 4.75 mg/mL in EtOH with ultrasonic and warming, ≥ 3.45 mg/mL in Water with ultrasonic and warming | Storage | Store at -20°C |
General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. |
Prepare stock solution | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.0385 mL | 10.1926 mL | 20.3853 mL |
5 mM | 0.4077 mL | 2.0385 mL | 4.0771 mL |
10 mM | 0.2039 mL | 1.0193 mL | 2.0385 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Average Rating: 5
(Based on Reviews and 30 reference(s) in Google Scholar.)GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *